Newly Diagnosed Glioblastoma
Conditions
Keywords
Cancer vaccine, Glioblastoma, Telomerase, TERT, PTPRZ1, Immunomodulation
Brief summary
This phase I/II trial evaluates the safety and the immunological efficacy of a cancer vaccine against 2 glioma-associated antigens in newly-diagnosed glioblastomas. The objectives of this study are as follows: Primary objective * phase 1: * to assess the maximum tolerated dose (MTD) and select the recommend Phase 2a dose * phase 2a: * to assess anti- TERT specific T cell responses at 2 months at the selected dose level Secondary objectives: * To assess Short and long-time immunological safety * To assess Evolution of anti-PTPRZ1 and anti-TERT immune T cell responses over time * To assess Progression free survival (RANO 2.0 criteria) * To assess Overall survival * To assess Quality of life by EORTC QLQ30 and BN20 questionnaires * To evaluate cardiac safety and monitor for the potential development of anti-melanin antibodies in a cohort of 8 patients enrolled in the Phase 2a study as well as objective of ancillary study: to determine the mechanism of action of potential tumour escape in GBM (T-cell lymphocyte phenotype; antigen expression and checkpoint inhibitors on tumour cells at relapse, if available), analysis of circulating antibodies against TERT epitope and/or melanin, and identification of predictive biomarkers of response. Ultimately, this trial together will lead to the implementation of future phase III trial in GBM. All patients enrolled in the study will receive standard treatment consisting of surgical resection of the tumor followed by radio-chemotherapy. Immunotherapy will begin 4 weeks after the completion of radiotherapy.
Detailed description
Prospective multicentre Phase I- IIa, non-comparative, non-randomised study with escalating doses for the Phase 1 part. Therapeutic cancer vaccines consisting of 1 or 2 antigenic peptidic formulations combined with an immune adjuvant: * A52-Mel: a TERT peptidic epitope adsorbed on synthetic melanin * A49-Mel: a PTPRZ1 peptidic epitope adsorbed on synthetic melanin (Phase 1 only) * Litenimod, a TLR9 agonist, as an adjuvant Phase 1: Patients will receive subcutaneous injections in the shoulders of both A49 and A52 at one of 3 pre-specified dose levels of peptides (50-100-250µg) + 1mg of Litenimod (fixed dose). Phase 2a: Patients will receive subcutaneous injections in the shoulder of A52 only at the dose selected in the phase 1 part + 1mg of Litenimod
Interventions
BIOLOGICALimmunization
One month after glioblastoma patients have completed the initial phase of treatment with concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide (5 days per month for 6 months). Immunizations will follow the standard schedule of a priming phase (D0, W2, W4, and W6) followed by a boost phase with one immunization every 2 months until progression, unacceptable toxicity, withdrawal of consent, or study end (at 12 months), whichever occurs first.
Sponsors
Assistance Publique - Hôpitaux de Paris
ALTEVAX SAS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age between 18 and 75 years old * free, informed and written consent signed * Histologically confirmed glioblastoma * Patients previously treated with concurrent radiotherapy (at least 45 Gy) with concomitant temozolomide, before the beginning of the 6 additional monthly cycles of temozolomide. Radiation therapy must have been completed 28 to 45 days prior to the first study treatment * Karnofsky Performance Status ≥ 60% * Phase 1 only: Patients must be human leukocyte antigen (HLA)-A2 positive. * Phase 1 only: PTPRZ1 expression in the tumor * Available tumor tissue for post hoc (retrospective) assessment of TERT promoter mutations and MGMT promoter methylation status * Life expectancy ≥ 3 months * Adequate organ function laboratory values within 15 days before initiation of treatment (see table in section 6.1) * Women or Male of childbearing potential (WOCBP) must use contraceptive methods during and for 180 days after the last dose of temozolomide or up to 120 days after the last dose of vaccine, whichever is longer (see section 6.3). No sperm donation during the study and until 7 months after the end of the treatment period. * Patient affiliated to the social security scheme
Exclusion criteria
* Known extracranial metastatic or leptomeningeal disease * Grade 4 astrocytoma IDH mutant * Steroid requirement \>10 mg prednisone daily (or equivalent) at time of inclusion * Patients with prior malignancy active within the last 3 years * Patients receiving immunomodulatory or immunosuppressive therapy * Carmustine wafers (GliadelR) implantation during surgery * Phase 1 only: patient eligible and willing to be treated with Optune (TTF fields) * History of autoimmune disease (lupus, rheumatoid arthritis, inflammatory bowel disease...) * Previous treatment with bevacizumab or other Vascular Endothelial Growth Factor (VEGF) antagonists * Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study. * Uncontrolled active systemic fungal, bacterial, viral, or other infection within the previous 4 weeks or requirement for intravenous (IV) antibiotics within the last two weeks * Breast-feeding or pregnant women. * Contra-indications to IRM * Contra-indications to investigational medicinal product and/or to auxiliary medicinal products * Participation to another interventional clinical trial, clinical investigation or another interventional study or being in the exclusion period at the end of a previous study * Patient unable to follow the procedures and constraints of the protocol * Patient under legal protection (protection of the court, or in curatorship or guardianship).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) for Phase 1 | 2 months | the maximum tolerated dose (MTD) based on the occurrence of dose limiting toxicity (DLT) |
| anti-TERT specific T cell responses (safety/efficay) for Phase 2 | 2 months | anti-TERT specific T cell responses by using IFN-gamma ELISPOT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of anti-PTPRZ1 specific T cell responses | over time | anti-PTPRZ1 specific T cell responses by using IFN-gamma ELISPOT |
| Overall survival | 12 months | The time interval from the start of treatment to the date of death from any cause. |
| Progression free survival | 12 months | Tumor response will be assessed using RANO 2.0 criteria |
| the evaluation of quality of life | 5 months | EORTC-QLQC30 questionnaire and BN20 module will be completed by each patient (Not all= 1; A little=2; Quite a bit= 3 ; Very Much=4) |
| Circulating anti-melanin antibodies | At M2 | in a cohort of 8 patients enrolled in the Phase 2a study |
| Cardiac safety | At month 2 | evaluated through 12-lead ECG assessments prior to injection, 3 hours post-injection, Day 7, Week 2, and Month 2), with a focus on QT-interval measurement. Additionally, cardiac biomarkers including troponin and pro-BNP will be monitored at baseline (Day 0), Week 2, and Month 2. assessed using 12-lead ECGs performed 3 hours after injection, on day 7, at week 2 and at |
Countries
France
Contacts
CONTACTAntoine CARPENTIER, Pr
STUDY_CHAIRAntoine CARPENTIER, Pr
APHP- Hôpital Saint Louis
Outcome results
None listed